Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy

Luengo‐Gil, Ginés; García‐Martínez, Elena; Cháves-Benito, Asunción; Conesa‐Zamora, Pablo; Manzano, Esther Navarro; González-Billalabeitia, Enrique; García-Garré, Elisa; Martínez-Carrasco, A.; Vicente, Vicente; Peña, Francisco Ayala de la

doi:10.1007/s13402-019-00450-2

Cited by 32 publications

(23 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies reported on the roles of the expression of certain miRNAs, such as miRNA-18a, miRNA-7 and miRNA-340, in the tumor tissue of patients who achieved PCR in predicting survival outcomes and response to chemotherapy. [24][25][26][27] The association between miRNA-21 expression and clinicopathological features in our study demonstrated an upregulation of this biomarker for clinical stages II and III, axillary lymph node metastasis and all breast cancer subtypes regardless of previous treatment with NAC. Conversely, there were no significant correlations of miRNA-21 expression with tumor size or tumor histological grade, which is in accordance with the findings of previous reports.…”

Section: Discussionsupporting

confidence: 54%

<p>Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy</p>

Sales

Silva

Leite

et al. 2020

BCTT

View full text Add to dashboard Cite

Introduction: MicroRNA-21 (miRNA-21) has been described as one of the most significantly upregulated miRNAs in human breast cancer. However, limited knowledge exists on miRNA-21 expression in breast cancer tissue after neoadjuvant chemotherapy (NAC). Purpose: The aim of this study was to assess miRNA-21 expression in the tumor tissues of Brazilian patients with breast cancer who underwent NAC and its correlation with clinicopathological variables. Patients and Methods: Utilizing qRT-PCR, miRNA-21 expression in tumor tissue was measured in a cohort of female patients with breast cancer who underwent NAC. The correlation of miRNA-21 expression with breast cancer molecular subtypes and other clinicopathological variables was also assessed. Results: A total of 55 patients were included in the study, and 28 (50.9%) underwent NAC. miRNA-21 was upregulated in patients with breast cancer, regardless of previous exposure to chemotherapy, molecular subtypes, tumor-node-metastasis (TNM) staging and lymph node status of the axilla. miRNA-21 expression did not differ between patients with breast cancer who achieved a pathologic complete response after NAC and healthy controls. Conclusion: miRNA-21 was upregulated in the tumor tissue of Brazilian patients with breast cancer regardless of NAC treatment, which reinforces its role as an "oncomiR" and a potential biomarker.

show abstract

Section: Discussionsupporting

confidence: 54%

<p>Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy</p>

Sales

Silva

Leite

et al. 2020

BCTT

View full text Add to dashboard Cite

show abstract

“…While researches proved that the remaining breast cancer cells are resistant to tamoxifen, which may associate the function of miR-18a to inhibit the translation of the estrogen receptor, but does not affect its transcription process. Moreover, miR-18a has been verified to link with the mitotic hallmarks and cell cycle checkpoints, and does not affect tumor invasion and migration [169]. In addition, in the study of castration treatment of prostate cancer, investigators justified the increase of miR-197 and miR-361-3p could silence tumor suppressors ARHGDIA or TAGLN2.…”

Section: Resistance With Drug Target-related Genesmentioning

confidence: 99%

miRNA-based biomarkers, therapies, and resistance in Cancer

et al. 2020

View full text Add to dashboard Cite

MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles in gene regulation, and their dysregulation is implicated in human diseases including cancer. A variety of miRNAs could take roles in the cancer progression, participate in the process of tumor immune, and function with miRNA sponges. During the last two decades, the connection between miRNAs and various cancers has been widely researched. Based on evidence about miRNA, numerous potential cancer biomarkers for the diagnosis and prognosis have been put forward, providing a new perspective on cancer screening. Besides, there are several miRNA-based therapies among different cancers being conducted, advanced treatments such as the combination of synergistic strategies and the use of complementary miRNAs provide significant clinical benefits to cancer patients potentially. Furthermore, it is demonstrated that many miRNAs are engaged in the resistance of cancer therapies with their complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians and improve patient prognosis. With the belief that studies about miRNAs in human cancer would have great clinical implications, we attempt to summarize the current situation and potential development prospects in this review.

show abstract

“…miRNAs plays an important role in cell proliferation, differentiation, and apoptosis, and its abnormal expression may be closely related to tumorigenesis (13). Emerging research continues to focus on miRNAs as potential markers for BC targeted therapy and patient prognosis prediction (14). Recent studies reveal that miRNAs may act as oncogenes or suppressor genes in BC by participating in different cellular pathways (15,16), including via targeting AQP1.…”

Section: Introductionmentioning

confidence: 99%

MiR-3194-3p Inhibits Breast Cancer Progression by Targeting Aquaporin1

Wei

Cai

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Increasing evidence indicates that the Aquaporin1 (AQP1) aberrant expression may be related to a wide variety of human cancers, including breast cancer (BC). In the present study, we explore the effects and possible mechanism of miR-3194-3p on the biological behaviors of BC. At first, miR-3194-3p is found to modulate AQP1 expression targeting the 3-UTR using miRNA target prediction algorithms. MiR-3194-3p expression is markedly downregulated, and AQP1 expression is upregulated in BC tissues compared with adjacent normal breast tissues. Moreover, the differential expression of miR-3194-3p and AQP1 are observed in four BC cells with different malignancy degree. Meanwhile, a significant negative correlation between AQP1 and miR-3194-3p expressions in tumor tissues from 30 BC patients is revealed. miR-3194-3p mimic remarkably inhibits cell proliferation, migration, and invasion as well as promotes apoptosis in MDA-MB-231 cells while miR-3194-3p inhibitors exert an opposite role in MCF-7 cells. Dual-luciferase reporter system demonstrates that AQP1 is a direct target gene of miR-3194-3p. Overexpression of AQP1 by pBABE-puro-AQP1 vector partially abrogates the effect of miR-3194-3p mimic in MDA-MB-231 cells. In short, our results suggest that miR-3194-3p suppresses BC cell proliferation, migration, and invasion by targeting AQP1, providing a novel insight into BC tumorigenesis and treatment.

show abstract

Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy

Cited by 32 publications

References 73 publications

<p>Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy</p>

<p>Mirna21 Expression in the Breast Cancer Tumor Tissue is Independent of Neoadjuvant Chemotherapy</p>

miRNA-based biomarkers, therapies, and resistance in Cancer

MiR-3194-3p Inhibits Breast Cancer Progression by Targeting Aquaporin1

Contact Info

Product

Resources

About